Prof. Dr. İrfan Çiçin

Gastrointestinal Tümörlerde Nütrisyonel Tedavi

Turkiye Klinikleri Medical Oncology - Special Topics, 2020

Source : OpenAlex

Optimal Cytoreduction is an Independent Prognostic Factor in Ovarian Carcinosarcoma: A Turkish Gynecologic Oncology Group Study

Journal of Oncological Sciences, 2020

DOI 10.37047/jos.2019-73073 Texte intégral en libre accèsSource : OpenAlex

Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study

Journal of Oncology Pharmacy Practice, 2020

DOI 10.1177/1078155220963535 PMID 33050804 Source : OpenAlex

Comparison of Neoadjuvant Chemotherapy and Bladder-Preserving Chemoradiation in Patients with Non-Metastatic, Muscle-Invasive Bladder Cancer: A Single-Center Experience

Journal of Oncological Sciences, 2020

DOI 10.37047/jos.2020-77532 Texte intégral en libre accèsSource : OpenAlex

Yaşlı Kanser Hastalarında İmmünoterapi

Turkiye Klinikleri Medical Oncology - Special Topics, 2020

Source : OpenAlex

Multicenter real life expeMulticenter real life experience of biological agents in patients with metastatic colorectal cancerrience of biological agents in patients with metastatic colorectal cancer

2020

Source : OpenAlex

Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Bursa Uludag University - AVESIS, 2020

Source : OpenAlex

PROGNOSTIC AND PREDICTIVE MARKERSOF FOLFIRI/AFLIBERCEPT IN PATIENTS WITHMETASTATIC COLORECTAL CANCER (TOG STUDY)Cihan Erol1, Mutlu Hızal2, Irem Bilgetekin3, Sinem Akbas4,Duygu Bayir Garbioglu5, Jamshid Hamdard6, Cagatay Arslan7,Alper Sevinc8, Ahmet Kucukarda9, Dilek Gurgenyatagi10, EmreCakir11, Aykut Demirkiran12, Murat Araz12, Sercan On13, IzzetDogan14, Atike Pinar Erdogan15, Sinan Koca16, Pinar Kubilay17,Onder Eren18, Deniz Tataroglu Ozyukseler19, Mahmut EmreYildirim19, Ebru Cilbir20, Emir Celik21, Aykut Bahceci22, HalilTaskaynatan23, Abdulkerim Oyman24, Gulhan Ipek Deniz25,Serkan Menenekse26, Engin Kut26, Ahmet Gulmez27, AbdullahSakin28, Erdinc Nayir29, Ramazan Acar30, Seda Kahraman1,Erdem Sen31, Ali Inal32, Serdar Turhal33, Ali Osman Kaya34, SemraPaydas35, Didem Tastekin14, Ilhan Hacıbekiroglu11, Irfan Cicin9,Ahmet Bilici6, Didem Sener Dede1, Muhammed Bulent Akinci1,Nil Molinas Mandel36, Berna Oksuzoglu3, Dogan Uncu2, BulentYalcin1, Mehmet Artac12, Mehmet Ali Nahit Sendur1

AYBU AVESIS, 2020

Source : OpenAlex

IMMUNOTHERAPY IN ELDERLY CANCER PATIENTS

Turkiye Klinikleri eBooks, 2020

DOI 10.5336/978-625-401-191-7_p106 Source : OpenAlex

Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

Trakya University's Institutional Open Access System (Trakya University), 2020

Source : OpenAlex

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Annals of Oncology, 2019

DOI 10.1093/annonc/mdz061 PMID 30796821 87 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

The Lancet Oncology, 2019

DOI 10.1016/s1470-2045(19)30668-0 PMID 31753727 70 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer

Journal of Clinical Oncology, 2019

DOI 10.1200/jco.19.01348 PMID 31751163 79 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

Journal of Oncology Pharmacy Practice, 2019

DOI 10.1177/1078155219883004 PMID 31653193 17 citations (Europe PMC) Source : OpenAlex

Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases

Bosnian Journal of Basic Medical Sciences, 2019

DOI 10.17305/bjbms.2019.4474 PMID 31999935 21 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

Clinical Colorectal Cancer, 2019

DOI 10.1016/j.clcc.2019.05.003 PMID 31221542 14 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer

Cancer Chemotherapy and Pharmacology, 2019

DOI 10.1007/s00280-019-03779-5 PMID 30680522 8 citations (Europe PMC) Source : OpenAlex

Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102.

PubMed, 2019

PMID 31786894 7 citations (Europe PMC) Source : OpenAlex

Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases

Archives of Gynecology and Obstetrics, 2019

DOI 10.1007/s00404-019-05160-6 PMID 30982145 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Is the Charlson Comorbidity Index a Prognostic Indicator for Toxicity and Mortality in Elderly Patients with Locally Advanced Rectal Cancer?

PubMed, 2019

PMID 31256595 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The albumin-bilirubin (ALBI) grade as a significant prognostic factor in colorectal cancer patients with liver metastases

Journal of Surgery and Medicine, 2019

DOI 10.28982/josam.597751 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.

Journal of Clinical Oncology, 2019

DOI 10.1200/jco.2019.37.15_suppl.4088 23 citations (OpenAlex) Source : OpenAlex

Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

Journal of Clinical Oncology, 2019

DOI 10.1200/jco.2019.37.15_suppl.4037 8 citations (OpenAlex) Source : OpenAlex

Pregnancy and Gastrointestinal Cancers

Springer eBooks, 2019

DOI 10.1007/978-3-030-18890-0_36 Source : OpenAlex

Effect of clinical and pathological features of gastrointestinal stromal tumors on overall survival and prognosis: Single center experience

Journal of Oncological Sciences, 2019

DOI 10.1016/j.jons.2019.10.003 Texte intégral en libre accèsSource : OpenAlex

Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides

Springer eBooks, 2019

DOI 10.1007/978-3-030-16792-9_42 Source : OpenAlex

GERİATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİMETASTATİK PROSTAT KANSERİ (KDMPK)HASTALARINDA 1. BASAMAK ANTİ- ANDROJENTEDAVİ SONUÇLARI- GERÇEK YAŞAM VERİSİ

AYBU AVESIS, 2019

Source : OpenAlex

GERIATRIK (≥75 YAS), KASTRASYON DIRENCLI METASTATIK PROSTAT KANSERI (KDMPK) HASTALARINDA 1. BASAMAK ANTI- ANDROJEN TEDAVI SONUCLARI- GERCEK YASAM VERISI

AYBU AVESIS, 2019

Source : OpenAlex

Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçları- Gerçek Yaşam Verisi

AYBU AVESIS, 2019

Source : OpenAlex

Kastrasyon Direncli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yas) Hastalarda 1. Basamak Dosetaksel Tedavi Sonucları- Gercek Yasam Verisi

AYBU AVESIS, 2019

Source : OpenAlex

Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?

Cancer Chemotherapy and Pharmacology, 2018

DOI 10.1007/s00280-018-3713-6 PMID 30374523 13 citations (Europe PMC) Source : OpenAlex

Crizotinib Efficacy in ALK-positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experince from Turkey

Van Yüzüncü Yıl University Academic Data Management System, 2018

Source : OpenAlex

Crizotinib Efficacy in ALK-positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

Bursa Uludag University - AVESIS, 2018

Source : OpenAlex

CRIZOTINIB EFFICACY IN ALK-POSITIVE ADVANCEDSTAGE NON-SMALL CELL LUNG CANCER PATIENTS: A REAL-WORLD EXPERIENCE FROM TURKEY

Kocaeli Üniversitesi - AVESİS, 2018

Source : OpenAlex

Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA)

Clinical and Applied Thrombosis/Hemostasis, 2018

DOI 10.1177/1076029617753538 PMID 29455568 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

New England Journal of Medicine, 2018

DOI 10.1056/nejmoa1717002 PMID 29972759 1 891 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

A retrospective study on potential drug interactions: A single center experience

Journal of Oncological Sciences, 2018

DOI 10.1016/j.jons.2018.06.001 7 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

European Journal of Cancer, 2018

DOI 10.1016/s0959-8049(18)30535-5 2 citations (OpenAlex) Source : OpenAlex

Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma.

PubMed, 2018

PMID 30358202 3 citations (Europe PMC) Source : OpenAlex

Bone-Targeted Therapy in Early Breast Cancer

Springer eBooks, 2018

DOI 10.1007/978-3-319-96947-3_18 1 citation (OpenAlex) Source : OpenAlex

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

Journal of Clinical Oncology, 2018

DOI 10.1200/jco.2018.36.4_suppl.207 99 citations (OpenAlex) Source : OpenAlex

Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology, 2018

DOI 10.1200/jco.2018.36.15_suppl.4090 26 citations (OpenAlex) Source : OpenAlex

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.

Journal of Clinical Oncology, 2018

DOI 10.1200/jco.2018.36.15_suppl.4019 13 citations (OpenAlex) Source : OpenAlex

Bone-Targeted Therapy in Advanced Breast Cancer

Springer eBooks, 2018

DOI 10.1007/978-3-319-96947-3_25 Source : OpenAlex

Effectiveness and safety of LMWH treatment in patients with cancer diagnosed with nonhigh-risk venous thromboembolism (VTE): Results of the Turkish observational study (TREBECA).

Journal of Clinical Oncology, 2017

DOI 10.1200/jco.2017.35.15_suppl.e21656 Source : OpenAlex

EFFECTIVENESS AND SAFETY OF LMWH TREATMENT IN CANCER PATIENTS DIAGNOSED WITH NON-HIGH RISK VENOUS THROMBOEMBOLISM (VTE) - RESULTS OF TURKISH OBSERVATIONAL STUDY (TREBECA)

Bursa Uludag University - AVESIS, 2017

Source : OpenAlex

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

The Lancet, 2017

DOI 10.1016/s0140-6736(17)32365-6 PMID 28916371 125 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

K-RAS and N-RAS mutations in testicular germ cell tumors

Bosnian Journal of Basic Medical Sciences, 2017

DOI 10.17305/bjbms.2017.1764 PMID 28426398 20 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis.

PubMed, 2017

PMID 28730760 2 citations (Europe PMC) Source : OpenAlex

Outcomes of Turkish National Breast Cancer Registry.

Journal of Clinical Oncology, 2017

DOI 10.1200/jco.2017.35.15_suppl.e12517 3 citations (OpenAlex) Source : OpenAlex